BeOne Medicines (ONC) FCF Margin (2015 - 2026)
BeOne Medicines' (ONC) quarterly FCF Margin came in at 10.45% in Q1 2026, up 1187.0% year-on-year from 0.81% in Q1 2025, and down 69.22% on a QoQ basis from 33.93% in Q4 2025.
BeOne Medicines (ONC) FCF Margin (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has 12 years of FCF Margin data on file, last reported at 10.45% in Q1 2026.
- On a quarterly basis, FCF Margin rose 1187.0% year-over-year to 10.45% in Q1 2026; TTM through Mar 2026 was 21.68%, a 1597.0% increase from a year earlier, with the FY2025 full-year figure at 20.03%, up 2557.0% from the prior year.
- FCF Margin for Q1 2026 stood at 10.45%, down from 33.93% in the prior quarter.
- Over the last five years, FCF Margin for ONC reached as high as 33.93% in Q4 2025 and fell as low as 182.47% in Q3 2022.
- Historically, FCF Margin has averaged 41.35% across 5 years, with a median of 5.87% in 2024.
- On a YoY basis, FCF Margin climbed as much as 19833 bps in 2022 and fell as far as 16976 bps in 2022.
- Year by year, FCF Margin stood at 115.64% in 2022, then surged by 72 bps to 32.44% in 2023, then jumped by 122 bps to 7.11% in 2024, then soared by 377 bps to 33.93% in 2025, then plunged by 69 bps to 10.45% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 10.45% in Q1 2026, 33.93% in Q4 2025, and 25.1% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 4.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.45% |
| Dec 31, 2025 | 33.93% |
| Sep 30, 2025 | 25.10% |
| Jun 30, 2025 | 16.98% |
| Mar 31, 2025 | -1.43% |
| Dec 31, 2024 | 7.11% |
| Sep 30, 2024 | 22.83% |
| Jun 30, 2024 | -5.87% |
| Mar 31, 2024 | -61.88% |
| Dec 31, 2023 | -32.44% |
| Sep 30, 2023 | 7.85% |
| Jun 30, 2023 | -80.12% |
| Mar 31, 2023 | -140.19% |
| Dec 31, 2022 | -115.64% |
| Sep 30, 2022 | -182.47% |
| Jun 30, 2022 | -115.20% |
| Mar 31, 2022 | -91.87% |
| Dec 31, 2021 | 54.11% |
| Sep 30, 2021 | -221.22% |
| Jun 30, 2021 | -313.54% |